tazverik
tazverik: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Epizyme, Inc. (EPZM) | Phase 2 |
Clinical Trials (1)
A Phase 2, Open-label, Single-Arm Clinical Trial to Investigate the Efficacy and Safety of Oral Tazemetostat for the Treatment of Adult Participants Age 18 and Over With Relapsed/Refractory Follicular Lymphoma Lacking the EZH2 Gain-of-Function (GOF) Mutation
FDA Decisions
Frequently asked questions
Who is developing tazverik?
tazverik is being developed by Epizyme, Inc..
How many clinical trials involve tazverik?
BioSniper tracks 1 clinical trial involving tazverik.
What is tazverik's latest FDA decision?
The most recent tracked FDA decision for tazverik is Approval for 1 INDICATIONS AND USAGE TAZVERIK is a methyltransferase inhibitor indicated for the treatment of: Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. ( 1.1 ) Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. ( 1.2 ) Adult patients with relapsed or re, dated January 23, 2020.
Get deeper analysis on tazverik
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis